---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145197"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:25:40.757070+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Taysha completes screening for Rett syndrome gene therapy trial; reports Q1 net loss of $17.6M

## Summary
- Screening completed for first adult patient in Phase 1/2 REVEAL trial of TSHA-102 for Rett syndrome; dosing expected Q2 2023.
- Initial available Phase 1/2 clinical data, primarily on safety, expected in Q2 2023.
- Net loss for Q1 2023 was $17.6M ($0.28 per share) vs. $50.3M ($1.32 per share) in Q1 2022.
- Cash and equivalents $63.4M as of March 31, 2023; expected to fund operations into Q1 2024.
- FDA meeting request for TSHA-120 (GAN) regulatory path expected Q2 2023; meeting anticipated Q3.

## SEC filing metadata
- accession: 0001193125-23-145197
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/0001193125-23-145197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/d431505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145197
- JSON: https://secwatch.observer/filing/0001193125-23-145197.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145197.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for quarter ended March 31, 2023.
  - Period: quarter ended March 31, 2023
  - Result: reported results
  source text: Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/0001193125-23-145197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.